Company intelligence / Profile preview

Valeos Pharma

Ownership: Private
Development stage: Other

Overview

Valeos Pharma produces EU-GMP certified pharmaceutical-grade medical cannabis, currently supplying approximately 1.5 tonnes annually to European markets. The company has entered a strategic partnership with Celadon Pharmaceuticals to double its production capacity and further improve quality, aiming for up to 3 tonnes per year. The collaboration will also support development toward finished cannabis-based medical preparations for patients across Europe.

Therapeutic areas: PsychiatryImmunologyNeurology
Modalities: PhytopharmaceuticalsSmall moleculePlant-derived compounds
Industry: Biotech

Drug pipeline

2 assets

Zkittlez

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Celadon Pharmaceuticals Plc

Beyond the preview

Go deeper on Valeos Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valeos Pharma.

Explore the full profile